Meeder Advisory Services Inc. Takes Position in IQVIA Holdings Inc. $IQV

Meeder Advisory Services Inc. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel.com reports. The fund acquired 2,092 shares of the medical research company’s stock, valued at approximately $404,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter valued at about $2,811,292,000. Geode Capital Management LLC raised its holdings in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after buying an additional 24,453 shares in the last quarter. Boston Partners lifted its position in IQVIA by 14.9% in the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IQV shares. BMO Capital Markets lifted their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. TD Cowen lifted their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Mizuho boosted their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $241.88.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. Company insiders own 1.70% of the company’s stock.

IQVIA Stock Up 3.0%

Shares of NYSE IQV opened at $256.66 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.30. The firm’s fifty day moving average is $211.74 and its 200 day moving average is $187.01. The company has a market cap of $42.25 billion, a price-to-earnings ratio of 31.84, a PEG ratio of 2.12 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has authorized a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.